Asparaginase Erwinia chrysanthemi received approval to treat patients with acute lymphoblastic leukemia (ALL) who had to discontinue treatment with Escherichia coli-derived asparaginase because of hypersensitivity, while calaspargase pegol-mknl was approved to treat pediatric and young adult patients with ALL. This evidence concerns the gene ASPG and acute lymphoblastic leukemia.